English
Regional settings| Spread | 0.63 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 86.95 |
| Open | 87.05 |
| 1-Year Change | -23.8% |
| Day's Range | 86.1 - 87.86 |
Founded in 2008, BioNTech is an innovative biotechnology company from Germany, specialising in the research, development and producing of active individualised immunotherapies. The company adheres to a patient-specific approach to treatment of serious diseases, such as cancer.
BioNTech shares a vision that every patient’s tumour is unique. It means that each patient’s treatment should be individualised. To implement the scientists’ ideas into practice, BioNTech has developed pioneering therapeutics for cancer and other rare and infectious diseases.
Headquartered in Mainz, Germany, the company is aimed at becoming the world’s leading biotechnology company for individialised cancer treatment. By 2020, BioNTech had more than 440 patients treated across 17 tumour types. The company has more than 1,300 employees and seven pharmaceutical partners.
In August 2018, the company partnered with the US pharmaceutical giant Pfizer Inc to develop mRNA-based vaccines for preventing influenza. In September 2019, BioNTech started working on the development of tuberculosis and HIV programmes and preclinical vaccine and immunotherapy candidates for the prevention of tuberculosis and HIV infections under an agreement with the Bill & Melinda Gates Foundation.
BioNTech stock floated on the NASDAQ stock exchange through a $150m initial public offering (IPO) in October 2019. Since then the BNTX stock quote has been traded on the US market.
In November 2020, BioNTech and Pfizer triggered the strongest wave of optimism on the stock market after they announced that their Covid-19 vaccine showed 90 per cent effectiveness during the phase-three clinical trials. The BioNTech share price soared 14 per cent the day after the announcement.
In 2019, BioNTech reported total revenues of about €109m. According to the estimates from Morgan Stanley, BioNTech and Pfizer can make around $13bn from vaccine sales, getting $6.5bn each if these estimates are correct.
Looking closely at the BioNTech stock price chart in 2020, we can see that BNTX stock has been trading in a range of $18.60-$115. Since the large sell-off in March 2020, the BioNTech SE (BNTX) stock quote grew from $28.55 on March 12, 2020, to $112.76 on November 10, 2020, which is a growth of 294 per cent.
Follow the BioNTech share price live on our interactive share price chart and build your own forecast for the famous German biotechnology company. Follow the latest BioNTech share news and spot the best levels to open profitable CFD trades at Capital.com.
